Navigation Links
NEURO-BIOTECH CORPORATION: Updates and latest developments
Date:11/1/2010

ease';s.eVar3=s.prop5; s.prop15='106438468';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106438468';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

BASEL, Switzerland, Nov. 1 /PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES).

In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed.

Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman's" version with explanations for common understanding.

We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market.

It is now the time to disclose the work done since the first "Update to Shareholders."

Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will b
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
2. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
5. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
6. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
7. China-Biotics Provides Further Updates on Qingpu New Facility
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. BioMS updates corporate strategy and adds leading healthcare investment banker
11. BioMS Medical updates University of Alberta equity position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... September 2, 2015 Biovista ... Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. Hierbei ... Genomics Institute. Biovista unterstützt mit seiner ... die Behandlung anderer Krankheiten als denen, für die ... und sein Team bei der Wylder Nation ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... Staff members will be attending Pharma Ed Resources upcoming educational seminar and ... of industry leading speakers, this timely conference will provide Updates & Case Studies ...
(Date:9/2/2015)... ... September 02, 2015 , ... The TS5-Q ... professional commercial video content, to analysis of athletic performance. Producing high-resolution slow-motion ... by too quickly to process with the naked eye. , Slow motion ...
(Date:9/1/2015)... 2, 2015 Swecure, ... Forschung und Entwicklung neuartiger Therapien für Störungen ... und Reizdarm konzentriert, erhält vom US Patent ... neues Medikament patentiert wird. Das Medikament basiert ... Kindern verhindert und Entzündungen vorbeugt.   ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... HARTFORD, Conn., Sept. 15 Genomas(R), a biomedical ... 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling ... Disease, was awarded by the National Institute of Mental Health. ... Ruano, M.D., Ph.D., President/CEO of Genomas and Director of Genetics ...
... , , , ... (Nasdaq: PARD ) today announced that 320 evaluable events (patient ... Efficacy After Relapse) trial, which is being conducted in accordance with a ... evaluating picoplatin in the treatment of small cell lung cancer (SCLC). ...
... , , , ... today the launch of HemoRANK(TM)-TKI, an in vitro assay service ... kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia). ... pharmaceutical companies that are developing novel therapeutic TKIs gain insight ...
Cached Biology Technology:Genomas Awarded $1.4 Million NIH SBIR Grant to Develop MRI+DNA Guided Biomarker System for Mental Illness 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 2Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 3Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 4Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target 5ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors 2ReachBio Launches HemoRANK-TKI Service Package for Predicting Myelotoxicity of New Tyrosine Kinase Inhibitors 3
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Today a plethora of dog genome-related materials are published, including ... and a series of primary research articles in the ... the publication by Nature of a high-quality draft ... researchers and the public with informative resources about canine genomics ...
... by Duke computer scientists and computational chemists have ... in an intricate three-dimensional puzzle-fit to regulate cell ... anticancer drugs to block the runaway cell division ... Significantly, their insights arose not just from meticulous ...
... scientists who first created "mighty mice" have developed, with ... agent that's more effective at increasing muscle mass in ... now in clinical trials. , The new agent is ... muscle-limiting protein myostatin. In mice, just two weekly injections ...
Cached Biology News:Scientists fetch useful information from dog genome publications 2Scientists fetch useful information from dog genome publications 3Scientists fetch useful information from dog genome publications 4'Computer-chemistry' yields new insight into a puzzle of cell division 2'Computer-chemistry' yields new insight into a puzzle of cell division 3'Computer-chemistry' yields new insight into a puzzle of cell division 4Mouse study: New muscle-building agent beats all previous ones 2
Request Info...
... Calmodulin Sepharose 4B, ... single-step purification of ... proteins.Purification of calmodulin-regulated ... eukaryotic cells. Category: ...
...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
Biology Products: